EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited

View source ↗

Summary

The EMA authorises Fulphila (pegfilgrastim) as a biosimilar, granting marketing authorization to Biosimilar Collaborations Ireland Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Febrile Neutropenia Prophylaxis in Cancer Patients
• Neutropenia

Drugs mentioned

• Fulphila (pegfilgrastim)

Snippet

Status: Authorised. MAH: Biosimilar Collaborations Ireland Limited. Decision date: 13/08/2026